Safety and Efficacy of NC120 for Improving Lipid Profile: A Double Blind Randomized Controlled Trial

Nafrialdi Nafrialdi, Johannes Hudyono, Frans D Suyatna, Arini Setiawati

Abstract


Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse effects such as myopathy and liver dysfunction. NC120 is herbal lipid lowering drug containing red yeast rice (RYR) extract, guggulipid, and chromium picolinate, and expected to have better safety profile. The aim of this study was to evaluate the efficacy and safety profiles of NC120 in lowering blood lipid. Methods: this was a double blind randomized clinical trial comparing NC120 with placebo in subjects with hypercholesterolemia. Two capsules of NC120 or placebo were administered twice a day for 28 days. Blood total-cholesterol, LDL-cholesterol, and triglyceride were measured on day-0, day-7, and day-28. Unpaired t-test was used to compare study parameter between groups, and one-way ANOVA was used to compare within group. Results: 25 subjects received NC120 and 24 subjects received placebo. Significant decrease of total cholesterol and LDL-cholesterol were observed since day-7 in NC120 group, while the changes in placebo group were not significant at all time of observation. No significant decrease of triglyceride was observed in NC120 group and in placebo group. Side effects were minor and comparable between the two groups. Conclusion: NC120 is effective in reducing total cholesterol and LDL-cholesterol, but not triglyceride. This drug shows a good safety profile, and thus can be considered for patients who can not tolerate statin drugs.

Keywords


Nutrafor; cholesterol; red yeast rice; guggulipid

References


Sherry L. Murphy BS, Jiaquan Xu MD, et al. Death: Final data for 2015. National Vital Statistics Reports. 2017;66(6):1-18.

Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment. Neth Heart J. 2017;25:231–42. DOI 10.1007/s12471-017-0959-2.

Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2016;37(39):2999. doi:10.1093/eurheartj/ehw272.

Rosenson RS. Statins: Actions, side effects and administration. http://www.uptodate.com/home. Accessed October 16, 2018.

Maha A, Al-Mohaissen, Martha J, Ignaszewski AP, Frohlich J. Statin-associated muscle adverse events, update for clinicians. Sultan Qaboos Univ Med J. 2016 Nov; 16(4): e406–e415. doi: 10.18295/squmj.2016.16.04.002.

NC120 Product Information. PT Novell Laboratories.

Journoud M, Jones PJH. Red yeast rice: a new hypolipidemic drug. Life Sci. 2004;74:2675-83.

Segura B. Red yeast rice: an easy way to lower cholesterol. Nutr Bytes. 2003;9(1):1-6.

Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann Intern Med. 2009;150:830–39.

Urizar NL, Moore DD. Guguipid, a nutural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303–13. doi: 10.1146/annurev.nutr.23.011702.073102.

U.S. Department of Health & Human Services National Institutes of Health. Red yeast rice. NCCIH 2012.

Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia.Cardiovasc. Drugs Ther. 1994; 8:659–64.

Ghorai M, Mandal SC, PalM, Pal SP, Saha BP. A comparative study on hypocholesterolaemic effect of allicin, whole germinated seeds of bengal gram and guggulipid of gum gugglu. Phytother. Res.2000;14:200-2.

Marmett B, Nunes RB. Effects of chromium picolinate supplementation on control of metabolic variables: A systematic review. J Food Nutr Res. 2016;4(10):633-9.

Marmett B, Nunes RB. Effects of chromium picolinate supplementation on control of metabolic variables: a systematic review. J Food Nutr Res. 2016;4:633-9.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Acta Medica Indonesiana